Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
ALPINE IMMUNE SCIENCES, INC. (NVLS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP has filed a Schedule 13D for ALPINE IMMUNE SCIENCES, INC. |
02/14/2023 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 7.9% stake in ALPINE IMMUNE SCIENCES, INC. |
02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.6% stake in ALPINE IMMUNE SCIENCES, INC. |
02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 6.8% stake in Alpine Immune Sciences, Inc. |
02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4% stake in Alpine Immune Sciences, Inc. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2022 |
SC 13G/A
| Omega Fund VI, L.P. reports a 8.2% stake in Alpine Immune Sciences, Inc. |
02/14/2022 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.4% stake in Alpine Immune Sciences, Inc. |
02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 7.3% stake in Alpine Immune Sciences, Inc. |
02/16/2021 |
SC 13G/A
| Avidity Partners Management LP reports a 6.2% stake in Alpine Immune Sciences, Inc. |
02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
07/27/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
02/10/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
02/09/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
03/22/2016 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
|
|